Patents by Inventor Max S. Wicha
Max S. Wicha has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20140011274Abstract: A small percentage of cells within an established solid tumor have the properties of stem cells. These solid tumor stem cells give rise to both more tumor stem cells and to the majority of cells in the tumor that have lost the capacity for extensive proliferation and the ability to give rise to new tumors. Thus, solid tumor heterogeneity reflects the presence of tumor cell progeny arising from a solid tumor stem cell. We have developed a xenograft model in which we have been able to establish tumors from primary tumors via injection of tumors in the mammary gland of severely immunodeficient mice. These xenograft assay have allowed us to do biological and molecular assays to characterize clonogenic solid tumor stem cells. We have also developed evidence that strongly implicates the Notch pathway, especially Notch 4, as playing a central pathway in carcinogenesis.Type: ApplicationFiled: December 14, 2012Publication date: January 9, 2014Applicant: The Regents of the University of MichiganInventors: Michael F. Clarke, Sean J. Morrison, Max S. Wicha, Muhammad Al-Hajj
-
Publication number: 20130142785Abstract: The present invention relates to compositions, methods, and kits for treating cancers with HER2 targeting agents and preventing resistance thereto. In particular embodiments, non-HER2-amplified cancers are treated with HER2 targeting agents, wherein the cancer stem cells in the cancer express HER2 and/or HER2 indicator marker. The present invention also relates to compositions, methods, and kits for detecting expression of HER2 and/or a HER2 indicator marker in non-HER2-amplified cancer samples from a subject, and identifying the subject as responsive to treatment with a HER2 targeting agent and/or treating the subject with a HER2 targeting agent.Type: ApplicationFiled: October 25, 2012Publication date: June 6, 2013Inventors: Max S. Wicha, Hasan Korkaya
-
Patent number: 8435746Abstract: The present invention relates to compositions and methods for treating, characterizing, and diagnosing cancer. In particular, the present invention provides a novel stem cell cancer marker, ALDH1, useful for the diagnosis, characterization, and treatment of solid tumor stem cells.Type: GrantFiled: July 6, 2010Date of Patent: May 7, 2013Assignee: The Regents of the University of MichiganInventors: Max S. Wicha, Gabriela Dontu, Christophe Ginestier, Emmanuelle Charafe-Jauffret, Suling Liu
-
Patent number: 8357491Abstract: A small percentage of cells within an established solid tumor have the properties of stem cells. These solid tumor stem cells give rise to both more tumor stem cells and to the majority of cells in the tumor that have lost the capacity for extensive proliferation and the ability to give rise to new tumors. Thus, solid tumor heterogeneity reflects the presence of tumor cell progeny arising from a solid tumor stem cell. We have developed a xenograft model in which we have been able to establish tumors from primary tumors via injection of tumors in the mammary gland of severely immunodeficient mice. These xenograft assay have allowed us to do biological and molecular assays to characterize clonogenic solid tumor stem cells. We have also developed evidence that strongly implicates the Notch pathway, especially Notch 4, as playing a central pathway in carcinogenesis.Type: GrantFiled: December 28, 2010Date of Patent: January 22, 2013Assignee: The Regents of the University of MichiganInventors: Michael F. Clarke, Sean J. Morrison, Max S. Wicha, Muhammad Al-Hajj
-
Publication number: 20120295350Abstract: The invention provides methods for treating cancer via administering to a patient having a solid tumor a therapeutically effective amount of an antibody against Delta-like ligand 4(D114) or other Notch pathway components. The solid tumor may comprise solid tumor stem cells.Type: ApplicationFiled: August 1, 2012Publication date: November 22, 2012Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Michael F. Clarke, Max S. Wicha, Muhammad Al-Hajj
-
Publication number: 20110092378Abstract: A small percentage of cells within an established solid tumor have the properties of stem cells. These solid tumor stem cells give rise to both more tumor stem cells and to the majority of cells in the tumor that have lost the capacity for extensive proliferation and the ability to give rise to new tumors. Thus, solid tumor heterogeneity reflects the presence of tumor cell progeny arising from a solid tumor stem cell. We have developed a xenograft model in which we have been able to establish tumors from primary tumors via injection of tumors in the mammary gland of severely immunodeficient mice. These xenograft assay have allowed us to do biological and molecular assays to characterize clonogenic solid tumor stem cells. We have also developed evidence that strongly implicates the Notch pathway, especially Notch 4, as playing a central pathway in carcinogenesis.Type: ApplicationFiled: December 28, 2010Publication date: April 21, 2011Inventors: Michael F. Clarke, Sean J. Morrison, Max S. Wicha, Muhammad Al-Hajj
-
Publication number: 20110033481Abstract: A small percentage of cells within an established solid tumor have the properties of stem cells. These solid tumor stem cells give rise both to more tumor stem cells and to the majority of cells in the tumor that have lost the capacity for extensive proliferation and the ability to give rise to new tumors. Thus, solid tumor heterogeneity reflects the presence of tumor cell progeny arising from a solid tumor stem cell. We have developed a xenograft model in which we have been able to establish tumors from primary tumors via injection of tumors in the mammary glad of severely immunodeficient mice. These xenograft assays have allowed us to do biological and molecular assays to characterize clonogenic solid tumor stem cells. We have also developed evidence that strongly implicates the Notch pathway, especially Notch 4, as playing a central pathway in carcinogenesis.Type: ApplicationFiled: April 12, 2010Publication date: February 10, 2011Inventors: MICHAEL F. CLARKE, MAX S. WICHA, MUHAMMAD AL-HAJJ
-
Patent number: 7850961Abstract: A small percentage of cells within an established solid tumor have the properties of stem cells. These solid tumor stem cells give rise both to more tumor stem cells and to the majority of cells in the tumor that have lost the capacity for extensive proliferation and the ability to give rise to new tumors. Thus, solid tumor heterogeneity reflects the presence of tumor cell progeny arising from a solid tumor stem cell. We have developed a xenograft model in which we have been able to establish tumors from primary tumors via injection of tumors in the mammary gland of severely immunodeficient mice. These xenograft assay have allowed us to do biological and molecular assays to characterize clonogenic solid tumor stem cells. We have also developed evidence that strongly implicates the Notch pathway, especially Notch 4, as playing a central pathway in carcinogenesis.Type: GrantFiled: September 29, 2006Date of Patent: December 14, 2010Assignee: The Regents of The University of MichiganInventors: Michael F. Clarke, Sean J. Morrison, Max S. Wicha, Muhammad Al-Hajj
-
Publication number: 20100291581Abstract: The present invention relates to compositions and methods for treating, characterizing, and diagnosing cancer. In particular, the present invention provides a novel stem cell cancer marker, ALDH1, useful for the diagnosis, characterization, and treatment of solid tumor stem cells.Type: ApplicationFiled: July 6, 2010Publication date: November 18, 2010Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Max S. Wicha, Gabriela Dontu, Christophe Ginestier, Emmanuelle Charafe-Jauffret, Suling Liu
-
Patent number: 7754206Abstract: The invention provides methods for treating cancer via administering to a patient having a solid tumor a therapeutically effective amount of an antibody against Delta-like ligand 4 (D114). The solid tumor may comprise solid tumor stem cells.Type: GrantFiled: December 1, 2006Date of Patent: July 13, 2010Assignee: The Regents of the University of MichiganInventors: Michael F. Clarke, Max S. Wicha, Muhammad Al-Hajj
-
Publication number: 20100136031Abstract: The present invention provides methods of treating cancer by administering an IL8-CXCR1 pathway inhibitor (e.g., an anti-CXCR1 antibody or Repertaxin) alone or in combination with an additional chemotherapeutic agent such that non-tumorigenic and tumorigenic cancer cells in a subject are killed. The present invention also provides compositions and methods for detecting the presence of and isolating solid tumor stem cells in a patient (e.g., based on the presence of CXCR1 or FBXO21).Type: ApplicationFiled: November 11, 2009Publication date: June 3, 2010Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Max S. Wicha, Christophe Ginestier
-
Patent number: 7713710Abstract: A small percentage of cells within an established tumor have the properties of stem cells. These solid tumor stem cells give rise both to more tumor stem cells and to the majority of cells in the tumor that have lost the capacity for extensive proliferation and the ability to give rise to new tumors. The solid tumor heterogeneity reflects the presence of tumor cell progeny arising from a solid tumor stem cell. This discovery is the basis for solid tumor stem cell compositions, methods for distinguishing functionally different populations of tumor cells, methods for using these tumor cell populations for studying the effects of therapeutic agents on tumor growth, and methods for identifying and testing novel anti-cancer therapies directed to solid tumor stem cells.Type: GrantFiled: May 24, 2007Date of Patent: May 11, 2010Assignee: The Regents of the University of MichiganInventors: Michael F. Clarke, Sean J. Morrison, Max S. Wicha, Muhammad Al-Hajj
-
Publication number: 20090004205Abstract: A small percentage of cells within an established solid tumor have the properties of stem cells. These solid tumor stem cells give rise both to more tumor stem cells and to the majority of cells in the tumor that have lost the capacity for extensive proliferation and the ability to give rise to new tumors. Thus, solid tumor heterogeneity reflects the presence of tumor cell progeny arising from a solid tumor stem cell. We have developed a xenograft model in which we have been able to establish tumors from primary tumors via injection of tumors in the mammary gland of severely immunodeficient mice. These xenograft assay have allowed us to do biological and molecular assays to characterize clonogenic solid tumor stem cells. We have also developed evidence that strongly implicates the Notch pathway, especially Notch 4, as playing a central pathway in carcinogenesis.Type: ApplicationFiled: January 9, 2007Publication date: January 1, 2009Inventors: Michael F. Clarke, Max S. Wicha, Muhammad Al-Hajj
-
Publication number: 20080261244Abstract: The present invention relates to the field of oncology and provides novel compositions and methods for diagnosing and treating pancreatic cancer. In particular, the present invention provides pancreatic cancer stem cells useful for the study, diagnosis, and treatment of solid tumors.Type: ApplicationFiled: January 24, 2008Publication date: October 23, 2008Applicant: The Regents of the University of MichiganInventors: Max S. Wicha, Diane M. Simeone, Michael F. Clarke
-
Publication number: 20080194022Abstract: A small percentage of cells within an established solid tumor have the properties of stem cells. These solid tumor stem cells give rise both to more tumor stem cells and to the majority of cells in the tumor that have lost the capacity for extensive proliferation and the ability to give rise to new tumors. Thus, solid tumor heterogeneity reflects the presence of tumor cell progeny arising from a solid tumor stem cell. We have developed a xenograft model in which we have been able to establish tumors from primary tumors via injection of tumors in the mammary gland of severely immunodeficient mice. These xenograft assay have allowed us to do biological and molecular assays to characterize clonogenic solid tumor stem cells. We have also developed evidence that strongly implicates the Notch pathway, especially Notch 4, as playing a central pathway in carcinogenesis.Type: ApplicationFiled: April 20, 2007Publication date: August 14, 2008Inventors: Michael F. Clarke, Sean J. Morrison, Max S. Wicha, Muhammad Al-Hajj
-
Publication number: 20080187938Abstract: The present invention relates to compositions and methods for treating, characterizing, and diagnosing cancer. In particular, the present invention provides a novel stem cell cancer marker, ALDH1, useful for the diagnosis, characterization, and treatment of solid tumor stem cells.Type: ApplicationFiled: September 24, 2007Publication date: August 7, 2008Applicant: The Regents of the University of MichiganInventors: Max S. Wicha, Gabriela Dontu, Christophe Ginestier, Emmanuelle Charafe-Jauffret, Suling Liu
-
Patent number: 7115360Abstract: A small percentage of cells within an established solid tumor have the properties of stem cells. These solid tumor stem cells give rise both to more tumor stem cells and to the majority of cells in the tumor that have lost the capacity for extensive proliferation and the ability to give rise to new tumors. Thus, solid tumor heterogeneity reflects the presence of tumor cell progeny arising from a solid tumor stem cell.Type: GrantFiled: August 2, 2001Date of Patent: October 3, 2006Assignee: Regents of the University of MichiganInventors: Michael F. Clarke, Sean J. Morrison, Max S. Wicha, Muhammad al-Hajj
-
Patent number: 6984522Abstract: A small percentage of cells within an established solid tumor have the properties of stem cells. These solid tumor stem cells give rise both to more tumor stem cells and to the majority of cells in the tumor that have lost the capacity for extensive proliferation and the ability to give rise to new tumors. The solid tumor heterogeneity reflects the presence of tumor cell progeny arising from a solid tumor stem cell. This discovery is the basis for solid tumor stem cell compositions, methods for distinguishing functionally different populations of tumor cells, methods for using these tumor cell populations for studying the effects of therapeutic agents on tumor growth, and methods for identifying and testing novel anti-cancer therapies directed to solid tumor stem cells.Type: GrantFiled: August 1, 2001Date of Patent: January 10, 2006Assignee: Regents of the University of MichiganInventors: Michael F. Clarke, Sean J. Morrison, Max S. Wicha, Muhammad Al-Hajj
-
Publication number: 20040037815Abstract: A small percentage of cells within an established solid tumor have the properties of stem cells. These solid tumor stem cells give rise both to more tumor stem cells and to the majority of cells in the tumor that have lost the capacity for extensive proliferation and the ability to give rise to new tumors. Thus, solid tumor heterogeneity reflects the presence of tumor cell progeny arising from a solid tumor stem cell. We have developed a xenograft model in which we have been able to establish tumors from primary tumors via injection of tumors in the mammary gland of severely immunodeficient mice. These xenograft assay have allowed us to do biological and molecular assays to characterize clonogenic solid tumor stem cells. We have also developed evidence that strongly implicates the Notch pathway, especially Notch 4, as playing a central pathway in carcinogenesis.Type: ApplicationFiled: August 25, 2003Publication date: February 26, 2004Inventors: Michael F. Clarke, Sean J. Morrison, Max S. Wicha, Muhammad Al-Hajj
-
Publication number: 20020119565Abstract: A small percentage of cells within an established solid tumor have the properties of stem cells. These solid tumor stem cells give rise both to more tumor stem cells and to the majority of cells in the tumor that have lost the capacity for extensive proliferation and the ability to give rise to new tumors. Thus, solid tumor heterogeneity reflects the presence of tumor cell progeny arising from a solid tumor stem cell. This discovery is the basis for solid tumor stem cell compositions, methods for distinguishing functionally different populations of tumor cells, methods for using these tumor cell populations for studying the effects of therapeutic agents on tumor growth, and methods for identifying and testing novel anti-cancer therapies directed to solid tumor stem cells.Type: ApplicationFiled: August 1, 2001Publication date: August 29, 2002Applicant: Regents of the University of MichiganInventors: Michael F. Clarke, Sean J. Morrison, Max S. Wicha, Muhammad Al-Hajj